1 / 10

Based on the Iron (Fe) and Atherosclerosis Study (FeAST)

Reduction of Iron Stores and Cardiovascular Outcomes in Patients with Peripheral Arterial Disease A Randomized Controlled Trial. Based on the Iron (Fe) and Atherosclerosis Study (FeAST). Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN; Galina Shamayeva, MS;

flynn-william
Download Presentation

Based on the Iron (Fe) and Atherosclerosis Study (FeAST)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Reduction of Iron Stores and Cardiovascular Outcomes in Patients with Peripheral Arterial Disease A Randomized Controlled Trial Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN; Galina Shamayeva, MS; John A. Baron, MD; Ronald L. Dalman, MD; David J. Malenka, MD; C. Keith Ozaki, MD; and Philip W. Lavori, PhD Published in The Journal of the American Medical Association February 14, 2007

  2. FeAST Trial: Background • Accumulation of iron in excess of physiologic requirements has been implicated in risk of cardiovascular disease because of increased iron-catalyzed free radical-mediated oxidative stress. • The objective of this study was to test the hypothesis that reducing body iron stores through phlebotomy will influence outcomes in a cohort of patients with symptomatic peripheral arterial disease (PAD). Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

  3. FeAST Trial: Study Design 1277 patients with symptomatic but stable PAD Multicenter. Randomized. Controlled. Single-Blinded. Analysis by intent-to-treat. Patients were stratified by hospital, age, and baseline smoking status, diagnosis of diabetes mellitus, ratio of high-density to low-density lipoprotein cholesterol level, and ferritin level. Excluding those with conditions likely to cause acute-phase increase of the ferritin level or with a diagnosis of visceral malignancy within the preceding 5 years R Iron-Reduction Group* n=636 Control Group n=641 Up to 3.5 years follow-up • Primary Endpoint: All-cause mortality • Secondary Endpoint: Death plus nonfatal myocardial infarction and stroke * Phlebotomy reduced iron stores with removal of defined volumes of blood at 6 mo. intervals Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

  4. FeAST Trial: Primary and Secondary Outcome Events Comparison of Control and Iron-Reduction Groups for Primary (All-Cause Mortality) and Secondary (Death Plus Nonfatal MI and Stroke) Outcome Events Abbreviations: CI, confidence interval; HR, hazard ratio; MI, myocardial infarction Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

  5. FeAST Trial: Kaplan-Meir Analysis of Primary Endpoint (All-Cause Mortality) • No statistically significant differences between treatment groups was observed for the primary endpoint of all-cause mortality (HR 0.85; 95% CI 0.67-1.08; p=0.17). Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

  6. FeAST Trial: Kaplan-Meir Analysis of Secondary Endpoint (Death Plus Nonfatal MI, or Stroke) • There were no statistically significant differences between treatment groups for the secondary endpoint (HR 0.88; 95% CI 0.72-1.07; p=0.20). • Neither the cumulative incidence nor the time to occurrence of other nonfatal peripheral, coronary, and cerebral vascular events during the follow-up differed between groups. Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

  7. FeAST Trial: Limitations • Because of lower than expected accrual, the study was underpowered overall and particularly underpowered to definitively assess outcomes in younger patients and smokers. • This study was single-blinded, and primary and secondary endpoints were adjudicated by a committee external to the study; nonetheless, concerns remain about possible bias, particularly in subgroup analyses. Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

  8. FeAST Trial: Limitations (cont.) • Patients with very high ferritin levels were excluded from the study, and the efficacy of iron reduction in individuals with extreme levels of iron stores is unknown. Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

  9. FeAST Trial: Summary • Preplanned analyses of the primary (all-cause mortality) and the secondary (death plus nonfatal MI and stroke) endpoints performed on the entire study cohort showed no effect of iron reduction. • However, there was a significant interaction with age (1of 5 prespecified biological stratifying factors), suggesting that a beneficial effect might exist in younger patients, and observation that coincides with findings of others. Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

  10. FeAST Trial: Summary (cont.) • The FeAST data show that it should be possible to test definitively whether controlling iron levels may reduce disease risk and additional research is needed to further define ferrotoxic diseases, stratifying risk reduction with intervention, and clarify mechanisms, especially in younger patients. Zacharski et al. JAMA; 2007 Feb. 297(6): 603-10.

More Related